Completed PHASE3 NCT00032435

Homocysteine Study (HOST)

CSP #453 - Homocysteinemia in Kidney and Endstage Renal Disease Study (HOST)

Sponsor: Abbott Diagnostics Division

Conditions End Stage Renal Disease Renal Failure

Interventions PAL-40 Active PAL-40 Placebo

Updated 7 times since 2017 Last updated: Oct 14, 2010 Started: May 31, 2001 Primary completion: Aug 31, 2006 Completion: Sep 30, 2006

Listed as NCT00032435, this PHASE3 trial focuses on End Stage Renal Disease and Renal Failure and remains completed. Sponsored by Abbott Diagnostics Division, it has been updated 7 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Aug 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Aug 2018 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott Diagnostics Division
Pan American Laboratories
US Department of Veterans Affairs

Data source: VA Office of Research and Development

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Bay Pines, United States , Birmingham, United States , Boston, United States , Buffalo, United States , Charleston, United States , Cleveland, United States , Dallas, United States , Dayton, United States , Denver, United States and 27 more locations